a prospective observational survey on the long-term effect of ldl apheresis on drug-resistant nephrotic syndrome

Clicks: 564
ID: 169340
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #1 of 12 articles by views in 2016 national conference on electrical, electronics and biomedical engineering, eleco 2016

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Background/Aims: LDL apheresis (LDL-A) is used for drug-resistant nephrotic syndrome (NS) as an alternative therapy to induce remission by improvement of hyperlipidemia. Several clinical studies have suggested the efficacy of LDL-A for refractory NS, but the level of evidence remains insufficient. A multicenter prospective study, POLARIS (Prospective Observational Survey on the Long-Term Effects of LDL Apheresis on Drug-Resistant Nephrotic Syndrome), was conducted to evaluate its clinical efficacy with high-level evidence. Methods: Patients with NS who showed resistance to primary medication for at least 4 weeks were prospectively recruited to the study and treated with LDL-A. The long-term outcome was evaluated based on the rate of remission of NS 2 years after treatment. Factors affecting the outcome were also examined. Results: A total of 58 refractory NS patients from 40 facilities were recruited and enrolled as subjects of the POLARIS study. Of the 44 subjects followed for 2 years, 21 (47.7%) showed remission of NS based on a urinary protein (UP) level Conclusions: Almost half of the cases of drug-resistant NS showed remission 2 years after LDL-A. Improvement of nephrotic parameters at termination of the LDL-A treatment was a predictor of a favorable outcome.
Reference Key
muso2015nephrona Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Eri Muso, Masatoshi Mune, Tsutomu Hirano, Motoshi Hattori, Kenjiro Kimura, Tsuyoshi Watanabe, Hitoshi Yokoyama, Hiroshi Sato, Shunya Uchida, Takashi Wada, Tetsuo Shoji, Tsukasa Takemura, Yukio Yuzawa, Satoru Ogahara, Satoshi Sugiyama, Yasuhiko Iino, Soichi Sakai, Yousuke Ogura, Susumu Yukawa, Yoshiki Nishizawa, Noriaki Yorioka, Enyu Imai, Seiichi Matsuo, Takao Saito
Are you one of these authors? Claim your profile
Journal 2016 national conference on electrical, electronics and biomedical engineering, eleco 2016
Year 2015
DOI
10.1159/000437338
URL
http://www.karger.com/Article/FullText/437338
Keywords
prospective study nephrotic syndrome urology long-term outcomediseases of the genitourinary system

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.